ESMO GI_ONCOBITES_TOP ABSTRACTS

Liquid biopsy-guided selection for anti-EGFR

re-treatment in RAS/BRAF wild-type (wt)

chemorefractory metastatic colorectal cancer patients

(mCRC pts): Results from the phase II randomized

PARERE trial

4O

Clinical utility of including circulating tumor DNA (ctDNA)

monitoring in standard of care (SoC) colorectal cancer (CRC)

surveillance

2O

ESMO GI 2025

COLORRECTAL

Tu canal independiente de oncología en español

Top resúmenes y presentaciones

Regístrate aquí para recibir más contenidos

Registrarse